Lilly Will Tap Ambrx’s ReCODE Technology To Develop Metabolic, CNS Candidates

Partnership aims to yield first-in-class or best-in-class therapeutic antibodies and improved variants of native proteins, Ambrx tells “The Pink Sheet” DAILY.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet